BMO Capital analyst Etzer Darout reiterates C4 Therapeutics (NASDAQ:CCCC) with a Outperform and maintains $20 price target.
BMO Capital Reiterates Outperform on C4 Therapeutics, Maintains $20 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.